(Q52672324)

5 May 2018

title

Novel therapies for malignant pleural mesothelioma. (English)

1 reference

5 May 2018

author name string

Arnaud Scherpereel

1

1 reference

5 May 2018

Frederic Wallyn

2

1 reference

5 May 2018

Steven M Albelda

3

1 reference

5 May 2018

Camille Munck

4

1 reference

5 May 2018

publication date

1 March 2018

1 reference

5 May 2018

Lancet Oncology Commission

published in

1 reference

5 May 2018

volume

19

1 reference

5 May 2018

issue

3

1 reference

5 May 2018

page(s)

e161-e172

1 reference

5 May 2018

Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

The European mesothelioma epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Asbestos: use, bans and disease burden in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Radiotherapy for the treatment of malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Prophylactic radiotherapy to prevent procedure-tract metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Second line therapy in malignant pleural mesothelioma: A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

FAK signaling in human cancer as a target for therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Germline BAP1 mutations predispose to malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Malignant pleural mesothelioma: from the bench to the bedside.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Spontaneous regression of thoracic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

New roads open up for implementing immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Oncology meets immunology: the cancer-immunity cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Checkpoint Blockade in Lung Cancer and Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Mesothelin-targeted agents in clinical trials and in preclinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Oncolytic Viral Therapy for Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Drugs that lack single-agent activity: are they worth pursuing in combination?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930100-1

7 January 2021

10.1016/S1470-2045(18)30100-1

Identifiers

DOI

1 reference

5 May 2018

1 reference

5 May 2018